Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Oct;71(10):7518–7525. doi: 10.1128/jvi.71.10.7518-7525.1997

Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.

M A Nowak 1, A L Lloyd 1, G M Vasquez 1, T A Wiltrout 1, L M Wahl 1, N Bischofberger 1, J Williams 1, A Kinter 1, A S Fauci 1, V M Hirsch 1, J D Lifson 1
PMCID: PMC192098  PMID: 9311831

Abstract

Mathematical modeling of viral replication dynamics, based on sequential measurements of levels of virion-associated RNA in plasma during antiretroviral treatment, has led to fundamental new insights into human immunodeficiency virus type 1 pathogenesis. We took advantage of the simian immunodeficiency virus (SIV)-infected macaque model to perform detailed measurements and mathematical modeling during primary infection and during treatment of established infection with the antiretroviral drug (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). The calculated clearance half-life for productively infected cells during resolution of the peak viremia of primary infection was on the order of 1 day, with slightly shorter clearance half-lives calculated during PMPA treatment. Viral reproduction rates upon discontinuation of PMPA treatment after 2 weeks were approximately twofold greater than those obtained just prior to initiation of treatment in the same animals, likely reflecting accumulation of susceptible target cells during treatment. The basic reproductive ratio (R0) for the spread of SIV infection in vivo, which represents the number of productively infected cells derived from each productively infected cell at the beginning of infection, was also estimated. This parameter quantifies the extent to which antiviral therapy or vaccination must limit the initial spread of virus to prevent establishment of chronic disseminated infection. The results thus provide an important guide for efforts to develop vaccines against SIV and, by extension, human immunodeficiency virus.

Full Text

The Full Text of this article is available as a PDF (263.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonhoeffer S., Coffin J. M., Nowak M. A. Human immunodeficiency virus drug therapy and virus load. J Virol. 1997 Apr;71(4):3275–3278. doi: 10.1128/jvi.71.4.3275-3278.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonhoeffer S., May R. M., Shaw G. M., Nowak M. A. Virus dynamics and drug therapy. Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6971–6976. doi: 10.1073/pnas.94.13.6971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cao Y., Ho D. D., Todd J., Kokka R., Urdea M., Lifson J. D., Piatak M., Jr, Chen S., Hahn B. H., Saag M. S. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses. 1995 Mar;11(3):353–361. doi: 10.1089/aid.1995.11.353. [DOI] [PubMed] [Google Scholar]
  4. Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
  5. De Boer R. J., Boucher C. A. Anti-CD4 therapy for AIDS suggested by mathematical models. Proc Biol Sci. 1996 Jul 22;263(1372):899–905. doi: 10.1098/rspb.1996.0133. [DOI] [PubMed] [Google Scholar]
  6. Goldstein S., Elkins W. R., London W. T., Hahn A., Goeken R., Martin J. E., Hirsch V. M. Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. J Med Primatol. 1994 Feb-May;23(2-3):75–82. doi: 10.1111/j.1600-0684.1994.tb00105.x. [DOI] [PubMed] [Google Scholar]
  7. Herz A. V., Bonhoeffer S., Anderson R. M., May R. M., Nowak M. A. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7247–7251. doi: 10.1073/pnas.93.14.7247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hirsch V. M., Fuerst T. R., Sutter G., Carroll M. W., Yang L. C., Goldstein S., Piatak M., Jr, Elkins W. R., Alvord W. G., Montefiori D. C. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 1996 Jun;70(6):3741–3752. doi: 10.1128/jvi.70.6.3741-3752.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hirsch V., Adger-Johnson D., Campbell B., Goldstein S., Brown C., Elkins W. R., Montefiori D. C. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol. 1997 Feb;71(2):1608–1620. doi: 10.1128/jvi.71.2.1608-1620.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  11. Klotman M. E., Kim S., Buchbinder A., DeRossi A., Baltimore D., Wong-Staal F. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5011–5015. doi: 10.1073/pnas.88.11.5011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Letvin N. L., King N. W. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Syndr. 1990;3(11):1023–1040. [PubMed] [Google Scholar]
  13. Marx P. A., Spira A. I., Gettie A., Dailey P. J., Veazey R. S., Lackner A. A., Mahoney C. J., Miller C. J., Claypool L. E., Ho D. D. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med. 1996 Oct;2(10):1084–1089. doi: 10.1038/nm1096-1084. [DOI] [PubMed] [Google Scholar]
  14. McLean A. R., Nowak M. A. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS. 1992 Jan;6(1):71–79. doi: 10.1097/00002030-199201000-00009. [DOI] [PubMed] [Google Scholar]
  15. Mellors J. W., Kingsley L. A., Rinaldo C. R., Jr, Todd J. A., Hoo B. S., Kokka R. P., Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995 Apr 15;122(8):573–579. doi: 10.7326/0003-4819-122-8-199504150-00003. [DOI] [PubMed] [Google Scholar]
  16. Mellors J. W., Rinaldo C. R., Jr, Gupta P., White R. M., Todd J. A., Kingsley L. A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996 May 24;272(5265):1167–1170. doi: 10.1126/science.272.5265.1167. [DOI] [PubMed] [Google Scholar]
  17. Mulder J., McKinney N., Christopherson C., Sninsky J., Greenfield L., Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994 Feb;32(2):292–300. doi: 10.1128/jcm.32.2.292-300.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nowak M. A., Bangham C. R. Population dynamics of immune responses to persistent viruses. Science. 1996 Apr 5;272(5258):74–79. doi: 10.1126/science.272.5258.74. [DOI] [PubMed] [Google Scholar]
  19. Nowak M. A., Bonhoeffer S., Loveday C., Balfe P., Semple M., Kaye S., Tenant-Flowers M., Tedder R. HIV results in the frame. Results confirmed. Nature. 1995 May 18;375(6528):193–193. doi: 10.1038/375193a0. [DOI] [PubMed] [Google Scholar]
  20. Nowak M. A., Bonhoeffer S., Shaw G. M., May R. M. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol. 1997 Jan 21;184(2):203–217. doi: 10.1006/jtbi.1996.0307. [DOI] [PubMed] [Google Scholar]
  21. O'Brien T. R., Blattner W. A., Waters D., Eyster E., Hilgartner M. W., Cohen A. R., Luban N., Hatzakis A., Aledort L. M., Rosenberg P. S. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996 Jul 10;276(2):105–110. [PubMed] [Google Scholar]
  22. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
  23. Phillips A. N. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science. 1996 Jan 26;271(5248):497–499. doi: 10.1126/science.271.5248.497. [DOI] [PubMed] [Google Scholar]
  24. Piatak M., Jr, Luk K. C., Williams B., Lifson J. D. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques. 1993 Jan;14(1):70–81. [PubMed] [Google Scholar]
  25. Piatak M., Jr, Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993 Mar 19;259(5102):1749–1754. doi: 10.1126/science.8096089. [DOI] [PubMed] [Google Scholar]
  26. Rowland-Jones S. L., McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol. 1995 Aug;7(4):448–455. doi: 10.1016/0952-7915(95)80087-5. [DOI] [PubMed] [Google Scholar]
  27. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., Whitby D., Sabally S., Gallimore A., Corrah T. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995 Jan;1(1):59–64. doi: 10.1038/nm0195-59. [DOI] [PubMed] [Google Scholar]
  28. Shearer G. M., Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today. 1996 Jan;17(1):21–24. doi: 10.1016/0167-5699(96)80564-0. [DOI] [PubMed] [Google Scholar]
  29. Stilianakis N. I., Boucher C. A., De Jong M. D., Van Leeuwen R., Schuurman R., De Boer R. J. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. J Virol. 1997 Jan;71(1):161–168. doi: 10.1128/jvi.71.1.161-168.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tsai C. C., Follis K. E., Sabo A., Beck T. W., Grant R. F., Bischofberger N., Benveniste R. E., Black R. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995 Nov 17;270(5239):1197–1199. doi: 10.1126/science.270.5239.1197. [DOI] [PubMed] [Google Scholar]
  31. Watson A., Ranchalis J., Travis B., McClure J., Sutton W., Johnson P. R., Hu S. L., Haigwood N. L. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol. 1997 Jan;71(1):284–290. doi: 10.1128/jvi.71.1.284-290.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  33. van Gemen B., v d Wiel P., van Beuningen R., Sillekens P., Jurriaans S., Dries C., Schoones R., Kievits T. The one-tube quantitative HIV-1 RNA NASBA: precision, accuracy, and application. PCR Methods Appl. 1995 Feb;4(4):S177–S184. doi: 10.1101/gr.4.4.s177. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES